Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR).
AUTOR(ES)
Nagel, S
RESUMO
The quantification of Bcr-Abl transcript numbers in chronic myelogenous leukemia (CML) patients described here uses simultaneous competitive PCR amplification of the target gene (Bcr-Abl) and a reference gene (porphobilinogen deaminase; Pbgd) together with a single composite competitor molecule for both targets based on heterologous sequences. Using this technique, Bcr-Abl transcript numbers could be reproducibly determined even in clinical samples known to harbour poor quality RNA.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=146207Documentos Relacionados
- Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
- Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.
- Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
- Prevention of product carry-over by single tube two-round (ST-2R) PCR: application to BCR-ABL analysis in chronic myelogenous leukemia.
- An analysis of multiplex-PCR in the detection of BCR-ABL transcripts in hematological disorders
